Breaking News

FDA Grants Fast Track Designation to LB-P8 for Treatment of PSC

The Fast Track designation underlines the need for treatment options to fulfill the unmet medical needs of people affected by primary sclerosing cholangitis.

Author Image

By: Charlie Sternberg

Associate Editor

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for LB-P8, LISCure Biosciences’ investigational drug for the treatment of primary sclerosing cholangitis (PSC), a rare, chronic, cholestatic liver disease with significant unmet medical needs.   Fast Track designation is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and address unmet medical needs. Fast Track designation allows for enhanced com...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters